BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 15561842)

  • 41. Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis.
    Castañeda X; García-De-la-Mària C; Gasch O; Pericàs JM; Soy D; Cañas-Pacheco MA; Falces C; García-González J; Hernández-Meneses M; Vidal B; Almela M; Quintana E; Tolosana JM; Fuster D; Llopis J; Dahl A; Moreno A; Marco F; Miró JM;
    J Antimicrob Chemother; 2021 May; 76(6):1539-1546. PubMed ID: 33837406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
    McGrath BJ; Kang SL; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2034-40. PubMed ID: 7811015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
    Huang V; Rybak MJ
    J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus.
    Leonard SN; Rolek KM
    J Antimicrob Chemother; 2013 Mar; 68(3):644-7. PubMed ID: 23152482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
    Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
    Mascio CT; Alder JD; Silverman JA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4255-60. PubMed ID: 17923487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1925-9. PubMed ID: 10858356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Leonard SN
    PLoS One; 2012; 7(7):e42103. PubMed ID: 22848719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
    Raad I; Hanna H; Jiang Y; Dvorak T; Reitzel R; Chaiban G; Sherertz R; Hachem R
    Antimicrob Agents Chemother; 2007 May; 51(5):1656-60. PubMed ID: 17353249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
    Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R
    J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J; Bravo-Molina A; Peña-Monje A; Hernández-Quero J
    J Antimicrob Chemother; 2012 Nov; 67(11):2682-5. PubMed ID: 22796888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.